

# ***Neuroimaging of HIV-Related CNS Complications for Non- Experts***



**Beau M. Ances, MD, PhD, MSc, FANA**  
**Associate Professor**  
**Departments of Neurology, Radiology,**  
**Biomedical Engineering, Microbiology**  
**Washington University in St. Louis**



**June 13, 2014**

***7<sup>th</sup> International Symposium on Neuropsychiatry and HIV  
Barcelona, Spain***

# ***Neuroimaging of HIV Associated Neurocognitive Disorders (HAND) for Experts***



**Beau M. Ances, MD, PhD, MSc, FANA**  
**Associate Professor**  
**Departments of Neurology, Radiology,**  
**Biomedical Engineering, Microbiology**  
**Washington University in St. Louis**



**June 13, 2014**

***7<sup>th</sup> International Symposium on Neuropsychiatry and HIV  
Barcelona, Spain***

# Beau M. Ances, MD, PhD, MSc

## Disclosure of Interest



**National Institute of Nursing Research (NINR) (R01NR012657, R01NR012907, R01NR014449)**



**National Institute of Mental Health (NIMH) (R21MH099979)**



**WUSTL Institute for Clinical and Translational Science (ICTS)**



**Alzheimer's Association New Investigator in Research Grant (NIRG)**



**WUSTL Center Women's Infectious Disease Research Pilot Grant (cWIDR)**

### Clinical Trials

**National Institute of Aging (NIA) (RC2AG036535)-  
Alzheimer's Disease  
Neuroimaging Initiative (ADNI)  
Avid Pharmaceuticals**



### Consultant

**None**

### Speakers Bureau

**None**

**I own no stocks or equity in any pharmaceutical company**

# Outline of Talk

- **Introduction:** To understand the pathophysiology of HIV associated neurocognitive disorders (**HAND**)
- **Methods:** To evaluate advanced neuroimaging methods for assessing HAND
- **Results:** To evaluate the effects of HIV, co-morbidities, aging, and highly active anti-retroviral therapy (HAART) in the brain using advanced neuroimaging.
- **Future:** 1) Timelines for biomarkers of HAND 2) Multi-center neuroimaging of HAND

# “Doc, I Am Getting More Forgetful”

- ◆ A 64 year old Caucasian male presents with mild cognitive changes over the past few years.
- ◆ For the past 2-3 years he has noted mild memory issues including: infrequently getting lost, sometimes misplacing objects (i.e. car keys), and occasionally missing appointments.
- ◆ Friends have noticed he sometimes repeats words during a conversation and cannot remember names of certain friends (“on the tip of my tongue”).

# “Doc, I Am Getting More Forgetful”- Part 2

**Past Medical History:** HIV (diagnosed in 1988), PCP (1990), Hepatitis C (1990), drug abuse (1980's), and neuropathy (1994), elevated cholesterol

No known family history of similar symptoms

**Meds:** Atripla (has been on numerous HAART regimens in the past), Neurontin, and Lipitor

## **Exam:**

Mental Status: 2/3 recall, 26 on MMSE, 24 on MoCA

Cranial nerves: 2-12 intact

Motor: Normal tone and bulk, 5/5 throughout


Sensory: Diminished sensation below the knees

Reflexes; 2+ upper extremities, 1+ patellar, 0 at ankles


Coordination/ Gait: Normal

# Diagnostic Tests

- ◆ CMP and CBC: normal
- ◆ Thyroid panel: normal
- ◆ Ammonia: 35
- ◆ UA: negative
- ◆ UDS: negative
- ◆ B12: 937
- ◆ Folic acid: 8.1
- ◆ RPR: negative
- ◆ CD4 cell count = 489 (Nadir: 54)
- ◆ Plasma HIV Viral Load= undetectable
- ◆ Neuroimaging: Unremarkable




# HAND Pathophysiology and Demographics






# HAND Pathophysiology



Blood Brain Barrier

# Amyloid Metabolism in HIV




Ortega and Ances, *J Neuroimmune Pharmacol*, 2014

HIV-

HIV+

AD



Rempel and Pulliam, *AIDS*, 2005

# HAND Criteria in the Research Setting- Are Additional Biomarkers Needed?


	Neurologically Normal (NN)	Asymptomatic Neurocognitive Impairment (ANI)	Mild Neurocognitive Disorder(MND)	HIV Associated Dementia (HAD)
Global Deficit Score (GDS)	0	0.5	0.5	>1
Impairment in $\geq 2$ Cognitive domains (> 1SD)	No	Yes	Yes	Yes ( > 2 SD)
Impairment in Activities of Daily Living	No	No	Yes- Mild	Yes- Marked

Antinori et al., *Neurology*, 2007


- No neuroimaging or cerebrospinal measures are included in the criteria.

# The Continuing NeuroHIV Puzzle: HAND in the Pre and Post-HAART Eras

*Pre-HAART*




*Post-HAART*



Adapted from: Heaton, et al. *Neurology* 2010. Also: Robertson, et al. *AIDS* 2007; Simioni, et al. *AIDS* 2010; Garvey *HIV Clin Trials* 2011; Cysique & Brew, *Journal of Neurovirology* 2011; Meyer et al. *Neuroepidemiology* 2013


- Incidence but not prevalence of HAND has declined with HAART

# What is the Relationship Between HIV and Aging in the Brain?





Clifford and Ances, *Lancet Infect Dis*, 2013

- **By 2015 ~ 50% of all HIV+ patients will be > 50 years old**




Effros et al. *CID*, 2008



# Advanced Neuroimaging Techniques

# Magnetic Resonance Spectroscopy (MRS) Measures Brain Metabolites




**NAA= N-acetyl aspartate  
( neuronal function)**

**Cho= Choline  
(membrane turnover)**

**Lac= Lactate  
(neuroinflammation)**


**Cre=Creatine  
(reference measure)**

# Volumetric Brain Segmentation is Performed on T1 Images






# Diffusion Tensor Imaging Measures White Matter Changes



*Isotropy*




FA = 0.0


**CSF and  
Grey Matter**



*Anisotropy*



FA = 0.4




FA = 0.7

**White Matter**



# Arterial Spin Labeling (ASL) Measures Cerebral Blood Flow (CBF)





Ances et al., *Neurology*, 2006

$$\text{Control} - \text{Tag} \propto \text{CBF (mL/100mL/min)}$$


# Resting State Functional Connectivity in Clinical Practice?



# Resting State Functional Connectivity Magnetic Resonance Imaging (rs- fcMRI) Measures Brain Correlations



# Graph Models of rs-fcMRI: The Next Level



# Graph Theory 202

## Hubness (Node importance)


**Closeness:** average weighted shortest path length between a given node and all other nodes (**A**, **B**)

**Eigenvector centrality:** centrality of a node depends on the centrality of that node's neighbor (**A'**, **B'**)





## Entropy (Disorder)

**Diversity:** measure of graph entropy (variability in connections at a given node) (**A**, **B**)


- Measures can be applied at the global, network, and node levels



# Pittsburgh Compound B (PiB) Imaging Measures Amyloid Deposition



PET Imaging -  
[<sup>11</sup>C]6-OH-BTA-1 (PiB)



# Neuroimaging Results






# Mechanisms of HIV-Related CNS Injury in the Setting of cART in Our Patient

Early impact of HIV in the CNS soon after seroconversion or “burnt out” state

Co-morbidities (substance abuse, co-infections, mood disorders)



Aging


Ongoing CNS immune activation and active virus

Delayed HAART exposure or toxicity due to cART within CNS

# Mechanisms of HIV-Related CNS Injury in the Setting of cART in Our Patient

**Early impact of HIV in  
the CNS soon after  
seroconversion**  
(diagnosed in 1988)

Co-morbidities  
(substance abuse,  
co-infections, mood  
disorders)




Aging

Delayed HAART  
exposure or toxicity  
due to cART within  
CNS

Ongoing CNS  
immune activation

# Acute and Early HIV Infection Reduces CBF






# Acute and Early HIV Infection Damages the White Matter

Fractional Anisotropy (FA)

19 HIV-  
62 AEH  
16 CHI




Wright et al.,  
*under review*



- Plasma neopterin, CSF and plasma VL, and CD4+ cell counts correlated with FA in CHI but not AEH.




# Duration of HIV Infection Affects the Corpus Callosum White Matter Integrity




**19 HIV- Controls**  
**62 AEH**  
**16 CHI**  
 All HIV+ are untreated





# rs-fcMRI is Diminished in Chronic HIV+ Individuals




HIV+ = 58  
HIV- = 53



# HAND Reduces Caudate CBF in Chronic HIV+ Individuals



# Brain Volumetrics Are Diminished in Chronic HIV+ Individuals



HIV- = 26, HIV+/HAART- = 26, HIV+/HAART+ = 26




# Mechanisms of HIV-Related CNS Injury in the Setting of cART in Our Patient

Early impact of HIV in the CNS soon after seroconversion or “burnt out” state

Co-morbidities (substance abuse, co-infections, mood disorders)

Aging



Delayed HAART exposure or toxicity due to cART within CNS



**Ongoing CNS immune activation and active virus**

(virologically suppressed)


# Neuroinflammation is Present in Chronic HIV+ Patients Using MRS



Ances et al., Archives of Neurology, 2007



# Virologically Suppressed Older HIV+ Patients (> 60 years old) Have Greater Functional Correlations Using Rs-fcMRI




# Mechanisms of HIV-Related CNS Injury in the Setting of cART in Our Patient

Early impact of HIV in the CNS soon after seroconversion or “burnt out” state

**Co-morbidities**  
(substance abuse, co-infections, mood disorders)

(Clade B, Hepatitis C (1992), and drug abuse (1980's), and male)



Ongoing CNS immune activation and active virus

Aging


Delayed HAART exposure or toxicity due to cART within CNS



# HIV Clade Subtype Does Not Affect Brain Volumetrics









## Corpus Callosum




Ortega et al., *J Neurovirol.*, 2013



# No Additive Effect of Hepatitis C (HCV) Co-infection on DTI Metrics





# HIV and Previous Methamphetamine Use Independently Reduce CBF





# HIV Status and Not Gender Affects Neuropsychological Performance and Neuroimaging Measures






# Mechanisms of HIV-Related CNS Injury in the Setting of cART in Our Patient

Early impact of HIV in the CNS soon after seroconversion or “burnt out” state

Co-morbidities (substance abuse, co-infections, mood disorders)




**Aging**  
(64 years old)

Ongoing CNS immune activation and active virus




Delayed cART exposure or toxicity due to HAART within CNS

# HIV and Aging Independently Reduce CBF







# HIV and Aging Independently Reduce Brain Volumetrics




# HIV and Aging Independently Reduce rs-fcMRI



**HIV+ = 58**  
**HIV- = 53**





# HIV Primarily Affects Hubs While Aging Affects Entropy at the Global and Network Levels





## GLOBAL

Closeness Centrality



Diversity



## NETWORK

### Closeness centrality

		HIV	Age	HIV:Age
DMN	p-value	<b>0.005587</b>	0.226942	0.440119
	beta	<b>-0.001408</b>	-0.000034	-0.000174
PAR	p-value	<b>0.032704</b>	0.255023	0.626612
	beta	<b>-0.003703</b>	-0.000070	-0.000130
CER	p-value	0.286310	0.167602	0.0938638
	beta	-0.022115	-0.000036	0.000484
CINGO	p-value	0.454033	0.582788	0.626612
	beta	-0.008279	-0.000025	0.000144
OCC	p-value	0.552404	0.255023	0.952956
	beta	-0.002890	-0.000175	0.000014
SMN	p-value	0.552404	0.255023	0.440119
	beta	-0.011797	-0.000275	0.000273


### Eigenvector Centrality

		HIV	Age	HIV:Age
DMN	p-value	0.754266	0.968081	0.808622
	beta	-0.007735	-0.000102	0.000187
PAR	p-value	0.754266	0.802798	0.808622
	beta	-0.009027	-0.000055	0.000217
CER	p-value	0.716851	0.802798	0.808622
	beta	0.002883	-0.000013	-0.000150
CINGO	p-value	0.448733	0.889757	0.808622
	beta	-0.005049	-0.000052	0.000043
OCC	p-value	0.273378	0.802798	0.808622
	beta	-0.006721	0.000047	0.000042
SMN	p-value	0.273378	0.802798	0.808622
	beta	-0.002816	0.000136	-0.000044


### Diversity

		HIV	Age	HIV:Age
DMN	p-value	0.845908	<b>0.000035</b>	0.291414
	beta	-0.000309	<b>0.000014</b>	0.000009
PAR	p-value	0.773990	0.05266136 <sup>†</sup>	0.883921
	beta	0.000028	0.000006	0.000001
CER	p-value	0.491484	0.263394	0.08233318 <sup>†</sup>
	beta	-0.000884	-0.000015	0.000018
CINGO	p-value	0.573612	0.05266136 <sup>†</sup>	0.08233318 <sup>†</sup>
	beta	-0.000436	-0.000010	0.000010
OCC	p-value	0.491484	0.263394	0.08233318 <sup>†</sup>
	beta	-0.000535	-0.000005	0.000021
SMN	p-value	0.845908	0.332862	0.187336
	beta	-0.000473	-0.000010	0.000012



# PiB Helps Distinguish AD from HAND



# Effects of HIV and Aging on Amyloid Deposition



MC-SUVR as Function of Age




Ortega and Ances, *J Neuroimmune Pharmacol.*, 2014

# Mechanisms of HIV-Related CNS Injury in the Setting of cART in Our Patient

Early impact of HIV in the CNS soon after seroconversion or “burnt out” state

Co-morbidities (substance abuse, co-infections, mood disorders)

Aging



Ongoing CNS immune activation and active virus


**Delayed HAART exposure or toxicity due to cART within CNS**

**Atripla (has been on numerous combination antiretroviral therapies (cART) in the past)**




# Study Design for Assessing Effects of HAART on CBF

Cross sectional




Longitudinal




# HAART Improves Resting CBF

**Cross-sectional**



**Longitudinal**



# Antiretroviral CNS Penetration-Effectiveness (CPE) Affects Neuroimaging Measures




**CPE**

← 1                      0.5                      0

	1	0.5	0
<b>NRTIs</b>	Abacavir	Emtricitabine	Didanosine
	Zidovudine	Lamivudine	Tenofovir
		Stavudine	Zalcitabine
<b>NNRTIs</b>	Delavirdine	Efavirenz	
	Nevirapine		
<b>PIs</b>	Amprenavir-r	Amprenavir	Nelfinavir
	Indinavir-r	Atazanavir	Ritonavir
	Lopinavir-r	Atazanavir-r	Saquinavir
		Indinavir	Saquinavir-r
			Tipranavir-r
<b>Fusion Inhibitors</b>			Enfuvirtide



Letendre et al., *Arch Neurol*, 2008



Ances et al., *J Neurovirol.*, 2008




# CPE Does Not Affect Neuropsychological Performance or Brain Volumetrics



Baker et al., under preparation

- Is monocyte efficacy score (MES) is associated with neuroimaging changes?
- MES has previously shown to be associated with neurocognitive impairment (Shikuma et al, *Antiviral Therapy* 2012)

# Additional Work-up of Our Patient



**PiB: negative**

**Reduced global CBF**


# Are We There Yet?

## Timeline of Biomarkers For HAND?





COLUMBUS DISCOVERS THAT WHEN EXPLORING, IT'S NOT SUCH A GREAT IDEA TO BRING THE FAMILY ALONG.

# Temporal Progression of Biomarkers in HAND




# Possible Mechanism(s) for Effects of HIV and HAART in the Brain Using Neuroimaging

HIV



Masliah et al, Ann Neurol 1997



Disruption or loss of Synaptodendritic communication

Normal Synaptodendritic Density

Normal CBF  
Normal rs-fcMRI




Reduced CBF  
Reduced rs-fcMRI



HAART

Continued low level Inflammation and virus present







# HIV and Aging: Strains on the Brain



Younger

Older

HIV-



HIV+



# Conclusions

- Advanced neuroimaging techniques can help identify brain dysfunction due to HAND.
- Effects of HIV in the brain can be observed soon after seroconversion.
- HIV can lead to a reduction in CBF (using ASL) and rs-fc (using BOLD).
- Additional co-morbidities may affect advanced neuroimaging methods
- HIV and aging independently affect the brain (using ASL, BOLD, volumetrics).
- AD may be differentiated from HAND (using PiB).
- HAART can improve CBF (using ASL). However, CPE does not affect neuroimaging measures.
- Advanced neuroimaging techniques should be considered in the evaluation of the effects of HIV in the brain and could be included in future HAND criteria.

# The Future of Neuroimaging



# HIV Neuroimaging Cohorts

Name	Participants	Scanner	MRS	Vol	DTI	ASL	BOLD
CHARTER	250 HIV+	1.5 T/ 3T	X	X	X		
MACS	190 HIV+/ 150 HIV-	1.5T/3T	X	X	X		
HIV Neuroimaging Consortium	180 HIV+/ 30 HIV-	1.5 T	X	X			
WHIS	56 HIV+/ 12HIV-	3T		X	X		X
PISCES- Spudich	100 HIV+/20 HIV-	4T	X	X	X		
WUSTL- Ances	400 HIV+/ 100 HIV-	3T		X	X	X	X
Hawaii- Chang	100 HIV+/70 HIV-	3T	X	X			
UCSF- Valcour	60 HIV+/20 HIV-	3T		X	X		
Northwestern- Ragin	50 HIV+/20 HIV-	3T		X	X		X
Stanford- Pfefferbaum & Sullivan	300 HIV+/100 HIV-	1.5 T		X	X		
UCSF VA- Meyerhoff	50 HIV+/ 30 HIV-	1.5T		X			
Brown- Cohen	100 HIV+ /50 HIV-	3T		X	X		
ANRS CO3 Aquitaine	215 HIV+	1.5T		X	X		

- **Limitations: few using advanced neuroimaging methods, few are longitudinal, and few have HIV- controls**

# AIDS Clinical Trial Group (ACTG) 5310




University of California  
San Francisco

Dr. Victor Valcour  
Dr. Diane Havlir



Dr. Judith Currier  
Dr. JJ Wang



Dr. Pablo Tebas  
Dr. Dennis Kolson




Dr. Ned Sacktor



Dr. Kristine Patterson  
Dr. Kevin Robertson

- Participants: 1 “phantom” subject at all 7 sites and 9 HIV+ patients from 7 sites
- Neuropsychological performance testing and advanced MRI (Volumetrics, ASL, and BOLD) obtained at all 7 sites.

# Central Neuroimaging Data Archive (CNDA) at WUSTL



<https://cnda.wustl.edu>

- Allows for access to national and international data (i.e. DIAN)
- Can handles longitudinal studies with multiple biomarkers
- Pipelines available for processing of advanced neuroimaging methods

# Acknowledgements

## ◆ Ances Neuroimaging Laboratory

- Liang Wang, MD
- Liz Westerhaus, MS
- Matt Brier
- Mario Ortega
- Patrick Wright
- Aaron Tannenbaum
- Laurie Baker (UMSL)
- Jodi Heaps (UMSL)



## ◆ Knight ADRC

- John Morris MD
- Tammie Benzinger MD, PhD
- David Holtzman MD
- Marc Raichle MD
- Anne Fagan PhD
- Chengjie Xiong PhD
- Avi Snyder MD, PhD
- Alison Goate PhD
- Randall Bateman MD

## ◆ Collaborators

- Robert Paul PhD- UMSL
- Serena Spudich MD- Yale
- Victor Valcour MD- UCSF
- Dan Stein MD- Capetown, SA
- John Joska MD- Capetown, SA
- Turner Overton MD- UAB
- Sarah Cross MD- Vanderbilt
- David Hass PhD- Vanderbilt



# Thank you for your attention

## Ances Neuroimaging Laboratory

at Washington University in St. Louis



<http://neuro.wustl.edu/research/researchlabs/anceslaboratory.htm>





*Please contact with questions, if interested in collaborations, or interested in post-doc positions:*

[bances@wustl.edu](mailto:bances@wustl.edu)

(314) 747- 8423




# Analysis of the Restless Brain







# Graph Theory 101



REGULAR NETWORK



SMALL-WORLD NETWORK




RANDOM NETWORK




# Graph Theory 101

## Path Length



Path Length ( $L$ ) from 5 to 7 = 5

## Clustering Coefficient



Neighbors of 1 in blue = 4 Actual connections in red = 2

Existing Connections between Neighbors / Possible Connections between Neighbors



$$CC_1 = \frac{2}{\binom{4}{2}} = \frac{2}{6} = .33$$

## Small Worldness

$$S = \frac{C/C^0}{L/L^0}$$

$S > 1$


## Modularity



# Potential HIV Reservoir in the CNS

- The detection of compartmentalized cerebrospinal fluid (CSF) HIV variants with respect to blood suggests existence of a CNS reservoir of HIV infection.
- Compartmentalized CNS HIV has been detected in early infection, though its origin is unknown.

## Thai Primary HIV Cohort




Spudich et al.,  
*CROI, 2013*

# Implications for the Clinic

- Viral seeding of the CNS occurs soon after infection.
- Attention to the virus in CNS remains critical as a reservoir can develop.
- Early intervention with anti-retroviral therapy (ART) may be beneficial but additional longitudinal studies needed.
- Lumbar puncture (LP) should be considered when new neurologic symptoms are present in a HIV+ patient, even with good virological control in the plasma.
- Other etiologies besides virological escape may account for neurocognitive impairment.

# HIV and Aging Independently Reduce NFL





# CNS Penetration-Effectiveness (CPE) Ranks



	4	3	2	1
<b>NRTIs</b>	Zidovudine	Abacavir	Lamivudine	Didanosine
		Emtricitabine	Stavudine	Tenofovir
				Zalcitabine
<b>NNRTIs</b>	Nevirapine	Delavirdine	Etravirine	
		Efavirenz		
<b>PIs</b>	Indinavir-r	Darunavir-r	Atazanavir	Nelfinavir
		Fosamprenavir-r	Atazanavir-r	Ritonavir
		Indinavir	Fosamprenavir	Saquinavir
		Lopinavir-r		Saquinavir-r
				Tipranavir-r
<b>Entry Inhs</b>	Vicriviroc	Maraviroc		Enfuvirtide
<b>Integrase Inhs</b>		Raltegravir		

# HIV Primarily Affects Hubs While Aging Affects

## Entropy: Node Level



Thomas et al., *under preparation*




## Nodal Diversity

- Nodes with higher centrality had greater decreases with HIV.
- Nodes with lower diversity had greater increases with Age.




# Effects of HIV and Aging on Brain Topology Are Similar for Edge Weights

**HIV**



**Aging**



Thomas et al., *under preparation*

- Changes in edge weight correspond to areas affected by HIV effect on closeness centrality
- Patterns of edge weight changes (increases and decreases) may explain diversity changes seen with Aging